| DC60454 |
BRD-K56819078
Featured
|
BRD-K56819078 is a small-molecule senolytics and significantly decreases senescent cell burden and mRNA expression of senescence-associated genes in the kidneys of aged mices. |
|
| DC65205 |
FTX-6476
Featured
|
FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models. |
|
| DC65207 |
CFT-8634
Featured
|
CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors. |
|
| DC65208 |
BAY-7081
Featured
|
BAY-7081 is a Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor with very good aqueous solubility. |
|
| DC65210 |
CFT1946
Featured
|
CFT1946 is an orally active and selective target ligand for BRAF kinase. |
|
| DC65211 |
KT-474
Featured
|
KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases. |
|
| DC65212 |
MK-8189
Featured
|
MK-8189 is a potent, orally active and selective PDE10A inhibitor with a Ki value of 29 pM. MK-8189 can be used in research of schizophrenia. |
|
| DC65213 |
CEE321
Featured
|
CEE321 is a potent pan JAK inhibitor in enzyme and cellular assays (IC50 = 54 nM). CEE321 potently inhibited biomarkers relevant to atopic dermatitis. |
|
| DC65214 |
CZS-241
Featured
|
CZS-241 is a Potent, Selective, and Orally Available Polo- Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia. |
|
| DC65215 |
AK-2292
Featured
|
AK-2292 is a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. |
|
| DC65216 |
BI‑3231
Featured
|
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. |
|
| DC65217 |
BAY-805
Featured
|
BAY-805 is a potent and selective USP21 inhibitor. BAY-805 is a non-covalent inhibitor with low nanomolar affinity for USP21 and high selectivity over other DUB targets as well as kinases, proteases, and other common off-targets. |
|
| DC65218 |
BGB-8035
Featured
|
BGB-8035 is a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK IC50 = 1.1 nM)for B‑Cell Malignancies and Autoimmune Diseases. |
|
| DC65220 |
IPG7236
Featured
|
IPG7236 is a CCR8 antagonist that through the modulation of regulatory T-cells and cytotoxic T (CD8+ T) cells, displays anticancer effects. IPG7236 is currently undergoing Phase 1 clinical trials in the treatment of advanced solid tumors. |
|
| DC65221 |
BAY-6096
Featured
|
BAY6096, a potent, selective, and highly water-soluble α2B antagonist with IC50 = 14 nM. |
|
| DC65222 |
A2A receptor antagonist 1
Featured
|
A2A receptor antagonist 1 is an antagonist of both adenosine A2A receptor and A1 receptor with Kis of 4 and 264 nM, respectively. |
|
| DC86120 |
LIPID 10
Featured
|
Lipid 10 is a novel ionizable cationic lipid be used for delivery of therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted with Lipid 10-LNP. |
|
| DC65223 |
YCT529
Featured
|
YCT529 is a potent, selective and orally active RAR-α inhibitor. |
|
| DC65224 |
LP0200
Featured
|
LP0200 is the prodrug of the oral allosteric IL-17A inactivator. |
|
| DC65227 |
GLPG2534
Featured
|
GLPG2534 is an IRAK4 inhibitor for use as a therapeutic for inflammatory skin diseases. |
|
| DC65228 |
TP0473292
Featured
|
TP0473292 is an adamantane carboxylic acid ester prodrug of TP0178894, a metabotropic glutamate 2 and 3 receptor antagonist for use as an antidepressant. TP0473292 has undergone phase 1 clinical trials for treatment of depression. |
|
| DC65229 |
SEQ-9
Featured
|
Overview. A common route of resistance to tuberculosis involves Mtb erm37 expression, which expresses an RNA methyltransferase that methylates the A2058 position of the 23S ribosome RNA, hindering macrolide antibiotic binding. |
|
| DC65230 |
QR-6401
Featured
|
QR-6401 is a highly potent and selective macrocyclic CDK2 inhibitor with IV50 of 0.37 nM. QR-6401 exhibits good selectivity against other closely related kinases, such as CDK1, CDK4, CDK6, CDK9 and GSK3β. QR-6401 demonstrates robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration. |
|
| DC65231 |
BDM2
Featured
|
BDM2(Newly disclosed HIV-1 antiretroviral) is the first integrase-LEDGF/p75 allosteric HIV-1 inhibitor to clear Ph. |
|
| DC65232 |
PF-6870961
Featured
|
|
|
| DC65233 |
JNJ-65234637
Featured
|
A protein-protein interaction inhibitor for a challenging-to-drug master transcription factor. |
|
| DC65234 |
compound 1
Featured
|
|
|
| DC65235 |
LY3154885
Featured
|
LY3154885 is a Human Dopamine D1 Receptor Positive Allosteric Modulator (D1 PAM EC50 = 11.7 nM) with an Improved Nonclinical Drug−Drug Interaction Risk Profile. |
|
| DC65236 |
AZ13824374
Featured
|
AZ13824374 is a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models. |
|
| DC65237 |
MAP855
Featured
|
MAP855 is a novel highly potent and selective MEK1/2 kinase inhibitor with equipotent inhibition of WT and mutant MEK1/2, whose drug-like properties allow further investigation in the mutant MEK setting upon BRAF/MEK therapy. |
|
